Delay in GH replacement therapy OK after craniopharyngioma treatment

A delay in growth hormone replacement therapy (GHRT) after childhood-onset craniopharyngioma treatment is not associated with the risk of recurrence or tumor progression, according to a study.

In this retrospective, observational, a cohort of 71 childhood-onset craniopharyngiomas treated with recombinant human growth hormone (rhGH), including 27 treated ≥12 after craniopharyngioma treatment and 44 treat <12 months, with 29 of those patients treated between 6-12 months.

In the 3 groups, the 2-year event-free survivals were 8.15%; 72.2%; and 72.4%, and the 5- years event-free survivals were 69.4%; 69.8%; and 72.4%.

By Log-rank test, event-free survival was not different between groups.

In univariate and multivariate analysis, the risk of craniopharyngioma new event was not associated with the GHRT time delay after craniopharyngioma treatment, the authors concluded.

Reference
Nguyen Quoc A, Beccaria K, Briceño LG, et al. Growth hormone and childhood-onset craniopharyngioma: When to initiate growth hormone replacement therapy? J Clin Endocrinol Metab. 2023;dgad079. doi: 10.1210/clinem/dgad079. Epub ahead of print. PMID: 36794424.